Alliance Pharma Past Earnings Performance
Past criteria checks 0/6
Alliance Pharma's earnings have been declining at an average annual rate of -36%, while the Pharmaceuticals industry saw earnings growing at 10.5% annually. Revenues have been growing at an average rate of 8.7% per year.
Key information
-36.0%
Earnings growth rate
-37.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 8.7% |
| Return on equity | -2.5% |
| Net Margin | -4.2% |
| Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Alliance Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 170 | -7 | 64 | 0 |
| 31 Mar 23 | 169 | -3 | 64 | 0 |
| 31 Dec 22 | 167 | 1 | 64 | 0 |
| 30 Sep 22 | 165 | 7 | 63 | 0 |
| 30 Jun 22 | 163 | 12 | 62 | 0 |
| 31 Mar 22 | 163 | 10 | 62 | 0 |
| 31 Dec 21 | 163 | 7 | 62 | 0 |
| 30 Sep 21 | 155 | 13 | 59 | 0 |
| 30 Jun 21 | 147 | 18 | 55 | 0 |
| 31 Mar 21 | 138 | 13 | 50 | 0 |
| 31 Dec 20 | 130 | 8 | 46 | 0 |
| 30 Sep 20 | 131 | 10 | 46 | 0 |
| 30 Jun 20 | 131 | 11 | 46 | 0 |
| 31 Mar 20 | 133 | 18 | 47 | 0 |
| 31 Dec 19 | 136 | 25 | 48 | 0 |
| 30 Sep 19 | 133 | 23 | 48 | 0 |
| 30 Jun 19 | 130 | 21 | 48 | 0 |
| 31 Mar 19 | 124 | 20 | 46 | 0 |
| 31 Dec 18 | 118 | 18 | 44 | 0 |
| 30 Sep 18 | 112 | 21 | 40 | 0 |
| 30 Jun 18 | 107 | 24 | 36 | 0 |
| 31 Mar 18 | 104 | 27 | 35 | 0 |
| 31 Dec 17 | 102 | 29 | 33 | 0 |
| 30 Sep 17 | 101 | 25 | 33 | 0 |
| 30 Jun 17 | 100 | 22 | 32 | 0 |
| 31 Mar 17 | 99 | 20 | 31 | 0 |
| 31 Dec 16 | 97 | 18 | 30 | 0 |
| 30 Sep 16 | 85 | 18 | 26 | 0 |
| 30 Jun 16 | 72 | 18 | 22 | 0 |
| 31 Mar 16 | 60 | 15 | 19 | 0 |
| 31 Dec 15 | 48 | 13 | 16 | 0 |
| 30 Sep 15 | 47 | 11 | 16 | 0 |
| 30 Jun 15 | 45 | 8 | 15 | 0 |
| 31 Mar 15 | 44 | 8 | 14 | 0 |
| 31 Dec 14 | 44 | 8 | 13 | 0 |
| 30 Sep 14 | 44 | 8 | 13 | 0 |
| 30 Jun 14 | 44 | 9 | 13 | 0 |
| 31 Mar 14 | 45 | 9 | 13 | 0 |
| 31 Dec 13 | 45 | 10 | 14 | 0 |
| 30 Sep 13 | 45 | 10 | 13 | 0 |
| 30 Jun 13 | 46 | 10 | 13 | 0 |
Quality Earnings: DVL is currently unprofitable.
Growing Profit Margin: DVL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DVL is unprofitable, and losses have increased over the past 5 years at a rate of 36% per year.
Accelerating Growth: Unable to compare DVL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DVL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.6%).
Return on Equity
High ROE: DVL has a negative Return on Equity (-2.55%), as it is currently unprofitable.